VHL vitasora health limited

diamyd shares surge on $625m diabetes deal

  1. 520 Posts.
    http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=54911

    snippet from the URL above

    The deal is also a boost for the field of immunotherapy, which was bolstered by the approval of Dendreon Corp.'s Provenge (sipuleucel-T) in prostate cancer. Strasbourg, France-based Transgene SA, also caught the wave, by taking in $181 million in a recent public offering. (See BioWorld International, June 9, 2010.)

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
2.7¢
Change
0.000(0.00%)
Mkt cap ! $46.40M
Open High Low Value Volume
2.8¢ 2.8¢ 2.6¢ $2.624K 96.30K

Buyers (Bids)

No. Vol. Price($)
1 28618 2.7¢
 

Sellers (Offers)

Price($) Vol. No.
2.8¢ 273136 1
View Market Depth
Last trade - 15.59pm 11/09/2025 (20 minute delay) ?
VHL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.